Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Depreciation and Depletion (2021 - 2022)

Rani Therapeutics Holdings has reported Depreciation and Depletion over the past 2 years, most recently at $126000.0 for Q4 2022.

  • Quarterly results put Depreciation and Depletion at $126000.0 for Q4 2022, up 8.62% from a year ago — trailing twelve months through Dec 2022 was $500000.0 (changed 0.0% YoY), and the annual figure for FY2025 was $900000.0, down 10.0%.
  • Depreciation and Depletion for Q4 2022 was $126000.0 at Rani Therapeutics Holdings, down from $141000.0 in the prior quarter.
  • Over the last five years, Depreciation and Depletion for RANI hit a ceiling of $141000.0 in Q3 2022 and a floor of $111000.0 in Q1 2022.